(XERS) Xeris Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98422E1038
Glucagon, Cortisol, Paralysis, Hypothyroidism, Injectables
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 74.5% |
| Value at Risk 5%th | 98.0% |
| Relative Tail Risk | -20.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.37 |
| Alpha | 90.24 |
| CAGR/Max DD | 1.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.680 |
| Beta | 1.006 |
| Beta Downside | 1.410 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.67% |
| Mean DD | 17.27% |
| Median DD | 14.77% |
Description: XERS Xeris Pharmaceuticals November 17, 2025
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a commercial-stage biopharma focused on endocrine and neurological disorders. Its marketed products include Gvoke (a ready-to-use glucagon for severe hypoglycemia), Keveyis (for primary periodic paralysis) and Recorlev (a cortisol synthesis inhibitor for Cushing’s syndrome). The firm’s pipeline features XP-8121, a once-weekly subcutaneous levothyroxine currently in Phase 3 for hypothyroidism. Incorporated in 2005, Xeris is headquartered in Chicago, Illinois.
As of the most recent filing (Q3 2024), Xeris reported approximately $45 million in total revenue, with Gvoke accounting for roughly 70 % of sales and a year-over-year growth rate of 18 %. The company held a cash runway of about $150 million, sufficient to fund operations through late 2026 under current burn rates. The endocrine market is expanding at a CAGR of ~6 % driven by an aging population and rising prevalence of diabetes, providing a favorable backdrop for Gvoke and XP-8121. Additionally, Recorlev is positioned against a fragmented Cushing’s-syndrome market valued at $1.2 billion, where the lack of oral agents creates a competitive moat.
If you’re looking to deepen your quantitative assessment of XERS, ValueRay’s analyst tools can help you model scenario-based valuations and compare peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-15.6m TTM) > 0 and > 6% of Revenue (6% = 16.0m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 15.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 40.51% (prev 38.31%; Δ 2.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 10.6m > Net Income -15.6m (YES >=105%, WARN >=100%) |
| Net Debt (-53.4m) to EBITDA (26.6m) ratio: -2.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (177.6m) change vs 12m ago 19.21% (target <= -2.0% for YES) |
| Gross Margin 83.54% (prev 78.47%; Δ 5.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 77.00% (prev 58.35%; Δ 18.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.47 (EBITDA TTM 26.6m / Interest Expense TTM 29.6m) >= 6 (WARN >= 3) |
Altman Z'' -5.76
| (A) 0.29 = (Total Current Assets 224.0m - Total Current Liabilities 116.2m) / Total Assets 370.2m |
| (B) -1.84 = Retained Earnings (Balance) -682.4m / Total Assets 370.2m |
| warn (B) unusual magnitude: -1.84 — check mapping/units |
| (C) 0.04 = EBIT TTM 14.0m / Avg Total Assets 345.6m |
| (D) -1.84 = Book Value of Equity -682.4m / Total Liabilities 371.1m |
| Total Rating: -5.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.89
| 1. Piotroski 5.0pt |
| 2. FCF Yield 1.94% |
| 3. FCF Margin 7.45% |
| 4. Debt/Equity -44.35 |
| 5. Debt/Ebitda -2.01 |
| 6. ROIC - WACC (= -3.17)% |
| 7. RoE 73.68% |
| 8. Rev. Trend 97.69% |
| 9. EPS Trend 83.82% |
What is the price of XERS shares?
As of December 05, 2025, the stock is trading at USD 6.73 with a total of 2,143,109 shares traded.
Over the past week, the price has changed by -6.27%, over one month by -32.02%, over three months by -14.16% and over the past year by +96.78%.
Over the past week, the price has changed by -6.27%, over one month by -32.02%, over three months by -14.16% and over the past year by +96.78%.
Is XERS a buy, sell or hold?
Xeris Pharmaceuticals has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy XERS.
- Strong Buy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the XERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.5 | 70.9% |
| Analysts Target Price | 11.5 | 70.9% |
| ValueRay Target Price | 8.9 | 31.6% |
XERS Fundamental Data Overview December 03, 2025
Market Cap USD = 1.07b (1.07b USD * 1.0 USD.USD)
P/E Forward = 65.3595
P/S = 4.0338
P/B = 3.3354
Beta = 0.922
Revenue TTM = 266.1m USD
EBIT TTM = 14.0m USD
EBITDA TTM = 26.6m USD
Long Term Debt = 219.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.19m USD (from shortTermDebt, last quarter)
Debt = 38.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.02b USD (1.07b + Debt 38.2m - CCE 91.6m)
Interest Coverage Ratio = 0.47 (Ebit TTM 14.0m / Interest Expense TTM 29.6m)
FCF Yield = 1.94% (FCF TTM 19.8m / Enterprise Value 1.02b)
FCF Margin = 7.45% (FCF TTM 19.8m / Revenue TTM 266.1m)
Net Margin = -5.88% (Net Income TTM -15.6m / Revenue TTM 266.1m)
Gross Margin = 83.54% ((Revenue TTM 266.1m - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 85.22% (prev 79.58%)
Tobins Q-Ratio = 2.76 (Enterprise Value 1.02b / Total Assets 370.2m)
Interest Expense / Debt = 19.03% (Interest Expense 7.27m / Debt 38.2m)
Taxrate = 0.0% (0.0 / 621.0k)
NOPAT = 14.0m (EBIT 14.0m * (1 - 0.00%))
Current Ratio = 1.93 (Total Current Assets 224.0m / Total Current Liabilities 116.2m)
Debt / Equity = -44.35 (negative equity) (Debt 38.2m / totalStockholderEquity, last quarter -861.0k)
Debt / EBITDA = -2.01 (Net Debt -53.4m / EBITDA 26.6m)
Debt / FCF = -2.69 (Net Debt -53.4m / FCF TTM 19.8m)
Total Stockholder Equity = -21.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.22% (Net Income -15.6m / Total Assets 370.2m)
RoE = 73.68% (negative equity) (Net Income TTM -15.6m / Total Stockholder Equity -21.2m)
RoCE = 7.06% (EBIT 14.0m / Capital Employed (Equity -21.2m + L.T.Debt 219.5m))
RoIC = 6.87% (NOPAT 14.0m / Invested Capital 203.8m)
WACC = 10.04% (E(1.07b)/V(1.11b) * Re(9.72%) + D(38.2m)/V(1.11b) * Rd(19.03%) * (1-Tc(0.0)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.40%
[DCF Debug] Terminal Value 63.27% ; FCFE base≈19.8m ; Y1≈13.0m ; Y5≈5.95m
Fair Price DCF = 0.55 (DCF Value 90.7m / Shares Outstanding 165.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 83.82 | EPS CAGR: 169.8% | SUE: -0.16 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 38.94% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.255 | Revisions Net=+0 | Growth EPS=+1125.0% | Growth Revenue=+27.9%
P/E Forward = 65.3595
P/S = 4.0338
P/B = 3.3354
Beta = 0.922
Revenue TTM = 266.1m USD
EBIT TTM = 14.0m USD
EBITDA TTM = 26.6m USD
Long Term Debt = 219.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.19m USD (from shortTermDebt, last quarter)
Debt = 38.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.02b USD (1.07b + Debt 38.2m - CCE 91.6m)
Interest Coverage Ratio = 0.47 (Ebit TTM 14.0m / Interest Expense TTM 29.6m)
FCF Yield = 1.94% (FCF TTM 19.8m / Enterprise Value 1.02b)
FCF Margin = 7.45% (FCF TTM 19.8m / Revenue TTM 266.1m)
Net Margin = -5.88% (Net Income TTM -15.6m / Revenue TTM 266.1m)
Gross Margin = 83.54% ((Revenue TTM 266.1m - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 85.22% (prev 79.58%)
Tobins Q-Ratio = 2.76 (Enterprise Value 1.02b / Total Assets 370.2m)
Interest Expense / Debt = 19.03% (Interest Expense 7.27m / Debt 38.2m)
Taxrate = 0.0% (0.0 / 621.0k)
NOPAT = 14.0m (EBIT 14.0m * (1 - 0.00%))
Current Ratio = 1.93 (Total Current Assets 224.0m / Total Current Liabilities 116.2m)
Debt / Equity = -44.35 (negative equity) (Debt 38.2m / totalStockholderEquity, last quarter -861.0k)
Debt / EBITDA = -2.01 (Net Debt -53.4m / EBITDA 26.6m)
Debt / FCF = -2.69 (Net Debt -53.4m / FCF TTM 19.8m)
Total Stockholder Equity = -21.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.22% (Net Income -15.6m / Total Assets 370.2m)
RoE = 73.68% (negative equity) (Net Income TTM -15.6m / Total Stockholder Equity -21.2m)
RoCE = 7.06% (EBIT 14.0m / Capital Employed (Equity -21.2m + L.T.Debt 219.5m))
RoIC = 6.87% (NOPAT 14.0m / Invested Capital 203.8m)
WACC = 10.04% (E(1.07b)/V(1.11b) * Re(9.72%) + D(38.2m)/V(1.11b) * Rd(19.03%) * (1-Tc(0.0)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.40%
[DCF Debug] Terminal Value 63.27% ; FCFE base≈19.8m ; Y1≈13.0m ; Y5≈5.95m
Fair Price DCF = 0.55 (DCF Value 90.7m / Shares Outstanding 165.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 83.82 | EPS CAGR: 169.8% | SUE: -0.16 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 38.94% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.255 | Revisions Net=+0 | Growth EPS=+1125.0% | Growth Revenue=+27.9%
Additional Sources for XERS Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle